# EDGAR Filing Document

**Accession Number:** 0001601830
**File Stem:** 0001209191-23-019041
**Filing Date:** 2023-3
**Character Count:** 8277
**Document Hash:** c5755e1e1ce6da1cc8befc9f83fb4fd1
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001209191-23-019041.hdr.sgml**: 20230315

**ACCESSION NUMBER**: 0001209191-23-019041

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20230313

**FILED AS OF DATE**: 20230315

**DATE AS OF CHANGE**: 20230315

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Gibson Christopher
- **CENTRAL INDEX KEY:** 0001856369

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40323
- **FILM NUMBER:** 23736677

**MAIL ADDRESS:**
- **STREET 1:** C/O RECURSION PHARMACEUTICALS
- **STREET 2:** 41 S. RIO GRANDE STREET
- **CITY:** SALT LAKE CITY
- **STATE:** UT
- **ZIP:** 84101
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** RECURSION PHARMACEUTICALS, INC.
- **CENTRAL INDEX KEY:** 0001601830
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 464099738
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 41S RIO GRANDE STREET
- **CITY:** SALT LAKE CITY
- **STATE:** UT
- **ZIP:** 84101
- **BUSINESS PHONE:** (385) 269-0203

**MAIL ADDRESS:**
- **STREET 1:** 41S RIO GRANDE STREET
- **CITY:** SALT LAKE CITY
- **STATE:** UT
- **ZIP:** 84101

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Recursion Pharmaceuticals, LLC
- **DATE OF NAME CHANGE:** 20140305

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Gibson Christopher<br><sub>(Last) (First) (Middle)</sub><br>C/O RECURSION PHARMACEUTICALS<br>41 S. RIO GRANDE STREET<br><sub>(Street)</sub><br>SALT LAKE CITY, UT 84101<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2023-03-13 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_Chief Executive Officer_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>RECURSION PHARMACEUTICALS, INC. [ RXRX ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Class A Common Stock | 2023-03-13 |  | C<sup>(1)(2)</sup> |  | 3000 | A | $0.00 | 941787 | D |  |
| Class A Common Stock | 2023-03-13 |  | G<sup>(1)</sup> |  | 3000 | D | $0.00 | 938787 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Stock Option (Right to Buy) | $8.55 |  |  |  |  |  |  | <sup>(3)</sup> | 2033-02-01 | Class A Common Stock | 0 |  | 813600 | D |  |
| Stock Option (Right to Buy) | $11.40 |  |  |  |  |  |  | 2022-02-04 | 2032-02-04 | Class A Common Stock | 0 |  | 5436 | D |  |
| Stock Option (Right to Buy) | $11.40 |  |  |  |  |  |  | <sup>(4)</sup> | 2032-02-04 | Class A Common Stock | 0 |  | 416350 | D |  |
| Stock Option (Right to Buy) | $2.48 |  |  |  |  |  |  | <sup>(5)</sup> | 2030-12-30 | Class A Common Stock | 0 |  | 687500 | D |  |
| Class B Common Stock | $0.00 | 2023-03-13 |  | C<sup>(1)(2)</sup> |  |  | 3000 | <sup>(6)</sup> | <sup>(6)</sup> | Class A Common Stock | 3000 | $0.00 | 6618834 | D |  |
| Class B Common Stock | $0.00 |  |  |  |  |  |  | <sup>(6)</sup> | <sup>(6)</sup> | Class A Common Stock | 0 |  | 535000 | I | by LAHWRAN-3 LLC<sup>(7)</sup> |
| Class B Common Stock | $0.00 |  |  |  |  |  |  | <sup>(6)</sup> | <sup>(6)</sup> | Class A Common Stock | 0 |  | 508000 | I | by LAHWRAN-4 LLC<sup>(8)</sup> |
| Class B Common Stock | $0.00 |  |  |  |  |  |  | <sup>(6)</sup> | <sup>(6)</sup> | Class A Common Stock | 0 |  | 123875 | I | by Gibson Family Trust<sup>(9)</sup> |

---

### Footnotes:

(1) Transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

(2) Represents the conversion of Class B Common Stock into Class A Common Stock.

(3) The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.

(4) The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.

(5) The option, originally for 1,500,000 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on January 31, 2021, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.

(6) Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date.

(7) The shares are held by LAHWRAN-3 LLC, of which the Reporting Person is a member and a manager.

(8) The shares are held by LAHWRAN-4 LLC, of which the Reporting Person is a member and a manager.

(9) The shares are held by the Gibson Family Trust, of which the Reporting Person serves as Trustee.

**Signature:** /s/ Jonathan Golightly, attorney-in-fact  
**Date:** 2023-03-15

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**